We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merrimack (MACK) Reports Wider-than-Expected Q1 Loss
Read MoreHide Full Article
Merrimack Pharmaceuticals, Inc. (MACK - Free Report) is a Cambridge, MA-based development-stage biopharmaceutical company focused on developing innovative therapies in combination with companion diagnostics for the treatment of cancer.
Being a development-stage company, Merrimack does not have any approved product in its portfolio yet. Hence, investor focus should remain on pipeline updates.
After the sale of its only marketed product, Onivyde, to Ipsen for $1 billion in 2017, Merrimack is focused on its three pipeline candidates. MM-121 is being developed as a combination therapy in two phase II studies for the treatment of lung and breast cancer. MM-141, a monoclonal antibody, is being evaluated in a phase II study in pancreatic cancer patients. The company is evaluating MM-310, an antibody, in solid tumors in phase I study.
The company’s track record has been mixed, with the company beating estimates in two of the last four quarters and missing the same twice, with an average negative earnings surprise of 40.7%.
Currently, Merrimack has a Zacks Rank # 3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Merrimack posted wider-than-expected loss in the first quarter of 2018. While our consensus called for a loss of $1.28 per share, the company reported a loss of $1.33.
Revenues: In the first quarter of 2018, the company did not recognize any revenues.
Other Update: The company reported research and development expenses of $13.1 million during the quarter, down 39.4%. General and administrative expenses declined 23.2% year over year to $4.3 million. Cash and cash equivalents and marketable securities decreased to $76.3 million as of Mar 31, 2018 from $93.4 million as of December 31, 2017.
Share Price Impact: The shares were inactive in pre-market trading.
Merrimack Pharmaceuticals, Inc. Price and EPS Surprise
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Merrimack (MACK) Reports Wider-than-Expected Q1 Loss
Merrimack Pharmaceuticals, Inc. (MACK - Free Report) is a Cambridge, MA-based development-stage biopharmaceutical company focused on developing innovative therapies in combination with companion diagnostics for the treatment of cancer.
Being a development-stage company, Merrimack does not have any approved product in its portfolio yet. Hence, investor focus should remain on pipeline updates.
After the sale of its only marketed product, Onivyde, to Ipsen for $1 billion in 2017, Merrimack is focused on its three pipeline candidates. MM-121 is being developed as a combination therapy in two phase II studies for the treatment of lung and breast cancer. MM-141, a monoclonal antibody, is being evaluated in a phase II study in pancreatic cancer patients. The company is evaluating MM-310, an antibody, in solid tumors in phase I study.
The company’s track record has been mixed, with the company beating estimates in two of the last four quarters and missing the same twice, with an average negative earnings surprise of 40.7%.
Currently, Merrimack has a Zacks Rank # 3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Merrimack posted wider-than-expected loss in the first quarter of 2018. While our consensus called for a loss of $1.28 per share, the company reported a loss of $1.33.
Revenues: In the first quarter of 2018, the company did not recognize any revenues.
Other Update: The company reported research and development expenses of $13.1 million during the quarter, down 39.4%. General and administrative expenses declined 23.2% year over year to $4.3 million. Cash and cash equivalents and marketable securities decreased to $76.3 million as of Mar 31, 2018 from $93.4 million as of December 31, 2017.
Share Price Impact: The shares were inactive in pre-market trading.
Merrimack Pharmaceuticals, Inc. Price and EPS Surprise
Merrimack Pharmaceuticals, Inc. Price and EPS Surprise | Merrimack Pharmaceuticals, Inc. Quote
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>